Zhitong Financial App News, 300630.SZ Pharmaceutical (PUL) announced that the company recently received the registration approval of voriconazole for injection issued by the State Drug Administration, indicating that the product is regarded as having passed the consistency evaluation of generic injections, and that Puli Pharmaceuticals is qualified to sell voriconazole for injection in China.

It is reported that voriconazole is a broad-spectrum triazole antifungal drug for the treatment of invasive aspergillosis, Candida albicans in patients with non-neutropenia, severe invasive infections caused by fluconazole-resistant Candida albicans (including Candida albicans), severe infections caused by actinomycetes and Fusarium oxysporum, mainly used in the treatment of patients with progressive and life-threatening fungal infections. Prevention of invasive fungal infections in high-risk patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).